Guardant360® CDx
First FDA-aproved liquid biopsy for advanced solid tumour treatment guidance
Guardant360® is a next-generation sequencing (NGS) liquid biopsy test that analyses circulating tumour DNA (ctDNA) from blood. Results are delivered in ~10 working days from sample receipt, enabling timely treatment decisions for patients with advanced solid tumours.
Oncologists managing patients with advanced solid tumours who need comprehensive genomic profiling to guide targeted therapy selection or identify clinical trial eligibility.
- Hematologic malignancies
- Early stage (stage I/II) cancers
- When disease is stable or responding to therapy
74 gene somatic panel and MSI-High status
| Step / Test | Accuracy | Notes |
|---|---|---|
| Sensitivity | ≥ 95% | |
| Specificity-SNV/CNA/Fusion | 100% | |
| Specificity-Indel | 95.2% |
2 × 10ml Streck Cell-Free DNA BCT® tubes
20 mL peripheral blood collected into 2 × Streck Cell-Free DNA BCT® tubes. Collected by a licensed healthcare professional.
Collection, packaging, and shipping must follow the Guardant 360 Blood Collection Kit (BCK) Instructions for Use, including tube type and transport requirements.
Guardant360® is available through Codex Genetics as the authorised distributor in Hong Kong. Please contact us for ordering, sample collection kits, and shipping instructions.
Samples must be collected and submitted through an authorised healthcare provider.
- Collect blood into Streck Cell-Free DNA BCT® tubes (room-temperature stable up to 14 days).
- Do NOT centrifuge. Ship tubes intact at ambient temperature; avoid freezing or >37°C.
- Include completed test requisition form. Address: Unit 220, 2/F, Building 16W, HKSTP, Pak Shek Kok, NT, Hong Kong.
Please contact us for pricing.
Please refer to the technical documentation: https://www.guardantcomplete.com/assets/pdf/Guardant360-CDx-Technical-Information-US.pdf
Guardant360® CDx detects somatic variants in 74 genes and MSI-High status. It is FDA-approved as a companion diagnostic for NSCLC treatments, such as TAGRISSO® (osimertinib), RYBREVANT™ (amivantamab-vmjw), and LUMAKRAS™ (sotorasib).
Hong Kong-based molecular diagnostics laboratory specialising in clinical genomics, precision oncology, and rare disease diagnosis. Accredited to ISO 27001 and GenQA standards.
© 2026 Codex Genetics Limited. All rights reserved.
